Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1

Evan Cantor · Ashley Meyer · Stephanie M. Morris · Judith L. Z. Weisenberg · Nicole M. Brossier

Received: 8 March 2022 / Accepted: 20 May 2022 / Published online: 1 June 2022
© The Author(s) 2022

Abstract

Background Low-grade gliomas (LGGs) occurring in children can result in many different neurologic complications, including seizures. MEK inhibitors are increasingly being used to treat LGG, but their effect on associated neurologic symptoms has not been established.

Results Here, we report a patient with neurofibromatosis type 1 (NF1), medically refractory epilepsy (MRE), and an extensive optic pathway glioma (OPG) who developed dose-dependent seizure control while being treated with selumetinib. Seizure frequency rebounded after dose reduction for cardiac toxicity, then improved, and finally ceased after restarting full dosing, allowing confidence in the cause of improvement.

Conclusion Selumetinib may have promise in epilepsy management in other children with NF1 or LGG.

Keywords Epilepsy · Seizure · Neurofibromatosis · NF1 · MEK inhibitor · Selumetinib

Abbreviations

LGG Low-grade glioma
NF1 Neurofibromatosis type 1
OPG Optic pathway glioma
EEG Electroencephalogram
MRI Magnetic resonance imaging
MRE Medically refractory epilepsy
AED Anti-epileptic drug
CBD Cannabidiol
MEKi MEK inhibitor
DEG Deep extensive glioma

Introduction

LGGs are common tumors in childhood and can result in neurologic complications, including seizures [1, 2]. In the following case, we describe a patient who achieved dose-dependent seizure control while on MEK inhibition for his NF1-associated OPG, with re-emergence of seizures after dose reduction and subsequent resolution of seizures upon return to full dose.

Results

The patient was brought to medical attention at age 3 due to spells concerning for possible seizures. Physical examination was notable for café-au-lait macules, axillary freckling, and left-sided facial weakness. Routine awake EEG revealed focal epileptiform discharges and prominent localized slowing in the right temporal region. MRI of the brain revealed bilateral OPG with extension into the hypothalamus, basal ganglia, and subcortical white matter (Fig. 1A), and mass effect on the right insular cortex and abnormal hippocampal signal intensity (Fig. 1B). He was diagnosed with NF1 and focal symptomatic epilepsy. He was started on oxcarbazepine and referred to Pediatric Neuro-Oncology, who recommended treatment if he progressed.

He re-established care with Pediatric Neuro-Oncology at 8 years old, while under consideration for vagal nerve stimulator implantation for MRE. At that time, seizures occurred in clusters every 5–6 days, with seizure frequency ranging between 1 and 10 seizures per day for 3–5 days during clusters, despite management with clobazam 0.3 mg/kg/day, levetiracetam 58 mg/kg/day, and CBD oil. A 24-h EEG
captured three electroclinical seizures that lateralized to the right hemisphere but were poorly localized. Repeat brain MRI revealed slow progression of his glioma over the prior 2 years with a new area of enhancement in his right frontal lobe (Fig. 1C, left). Examination was notable for dysarthria, left lower facial weakness, left upper extremity weakness, and mild circumduction of left lower extremity while walking. His mother also reported concerns regarding academic performance despite having an individualized education plan in place. Family refused standard of care therapy with carboplatin and vincristine, but agreed to MEK inhibitor (MEKi) treatment. The patient was started on 25 mg/m² selumetinib BID.
After 12 weeks, the patient’s mother noted significantly decreased seizure frequency with improved academic performance. Repeat brain MRI showed stable mass size but interval reduction in enhancement of the right frontal lesion (Fig. 1C, right), suggestive of treatment response. Unfortunately, he displayed evidence of cardiac toxicity on routine evaluation at this time (asymptomatic decline in left ventricular ejection fraction, 63% to 47%). Selumetinib was held, then reinitiated at 50% dosing upon subsequent normalization of echocardiogram findings.

On dose-reduced selumetinib, the patient’s mother reported that seizure frequency increased to pre-treatment baseline. Given the re-emergence of poorly controlled seizures, the family and treatment team both aimed to resume 100% dosing. He was started on afterload reduction with enalapril for cardioprotection and escalated back to 100% selumetinib dosing the following month.

Four weeks after restarting on full dose, the patient’s mother again reported a drastic improvement of both seizure frequency and academic performance. Improvements in alertness, left-sided weakness, and gait were also noted on neurologic examination. Currently, the patient remains seizure-free on full-dose selumetinib with stable disease on brain MRI. A recent 24-h EEG captured no electrographic or clinical seizures.

Discussion

NF1 and epilepsy In addition to the propensity to develop nervous system tumors, patients with NF1 have an increased risk of epilepsy, with 4–9.5% of patients developing seizures vs 1–2% in the general population [3, 4]. Focal sources — most commonly CNS tumors or mesial temporal sclerosis [4] — are frequently identified in NF1 patients with unprovoked seizures [3, 4], with 75% of patients demonstrating lateralizing epileptiform foci on EEG [3].

While children with NF1 are at increased risk of developing LGGs, these typically arise in the optic pathway [5] or brainstem [6], locations usually not associated with seizures. In contrast, this particular case may be more illustrative of the recently described “deep extensive gliomas” (DEGs) in children with NF1, which involve bilateral temporal lobes, basal ganglia, and thalami in addition to the optic pathway and may have a more severe clinical course [7]. Thirty-three percent of reported DEGs were associated with epilepsy [7]. It is unclear if standard treatment will improve seizure control in these cases, although decreased seizure frequency has been observed with treatment of some sporadic LGGs [8].

Importantly, not all patients with NF1-associated epilepsy have focal findings on imaging or EEG [3, 4], suggesting that genetic mutation alone may predispose to the development of seizure. In support of this hypothesis, patients with other genetic syndromes resulting in increased MAPK pathway activation, such as Noonen’s [9], tuberous sclerosis (TSC) [10, 11], or SYNGAP1 deficiency [12], have an increased incidence of epilepsy [11, 13, 14]. MAPK signaling has also been implicated in epilepsy outside of the context of germline mutation — microarray data from hippocampal tissue at the time of spontaneous seizure [16]. In addition, BRAF V600E mutation in early brain development (as hypothesized to occur in sporadic pediatric LGG) results in both mutant neurons and glia in murine models; mutation induces epileptogenic changes in the former [2]. Although this patient’s seizures were clearly focal in origin, it is possible that MAPK activation due to NF1 germline mutation in neuronal cells might contribute to the severity of his epilepsy and predict response to MEK inhibition. Notably, MEK inhibition has resulted in reduced seizure activity in mouse models of TSC [11] and in the Krushinsky–Molodkina rat [17], a genetic rat model of audiogenic seizures in which increased ERK activation is observed in glutamatergic neurons [18].

Potential mechanisms of action While the mechanism by which MEK inhibition might decrease epileptogenic activity has not been established, abnormalities of both glutamatergic and GABAergic pathways have been identified in MAPK-activated murine models. For example, expression of a constitutively active MEK1 (caMEK1) mutant in the murine brain results in spontaneous seizures, a phenotype dependent on increased eIF4E-mediated translation of the NMDA glutamate receptor NR2B subunit downstream of activated ERK in neurons [19]. When specifically targeted to GABAergic-interneurons, caMEK1 leads to spontaneous epileptiform activity accompanied by reduced inhibitory synapses on excitatory glutamatergic neurons [20]. Together, this suggests that MEKi may decrease aberrant neuronal excitability in NF1 by reducing glutamatergic stimulation and/or increasing GABAergic signaling.

Biologically targeted agents for treatment for epilepsy To our knowledge, this case is the first to describe the effective treatment of epilepsy with a MEKi in a human patient. This may be in part because therapeutic trials of MEKi efficacy in LGGs have thus far excluded patients with MRE [21, 22]. Frequent adjustments of AEDs may also make attribution of response difficult. Notably, in this case, a dose-dependent response to MEK inhibition was observed without concurrent changes in AEDs, allowing us to be more confident in the cause of improvement. Importantly, this patient’s tumor
was stable in size despite decreased enhancement with treatment, suggesting that objective response by RANO criteria [23] is not necessary for improved seizure control.

**Conclusion**

In this case, our patient appeared to have dose-dependent seizure control while receiving MEK inhibition for his glioma. This suggests that MEKi may be beneficial in the treatment of seizures in other children with brain tumors or with genetic disorders affecting the RAS/MAPK pathway. Further data from multiple patients with confirmatory EEG and neuropsychosocial testing will be needed to confirm these findings.

**Author contribution** Writing, original draft, E.C., A.M., and N.M.B.; writing–review and editing, S.M.M., J.L.Z.W., and N.M.B.; supervision, N.M.B.; funding acquisition, N.M.B. All authors have reviewed and agreed to the content of the manuscript.

**Funding** This work is funded by grants from Alex’s Lemonade Stand Foundation (18–12558 to N.M.B.), Hyundai Hope on Wheels (DR-2019–672 to N.M.B.), the National Institute of Child Health & Human Development (K12HD076244 to N.M.B.), and the Neurofibromatosis Therapeutic Acceleration Program (NTAP 210112 to N.M.B.).

**Declarations**

**Conflict of interest** On behalf of all authors, the corresponding author states that there is no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430
2. Koh HY, Kim SH, Jang J, Kim H, Han S, Lim JS, Son G, Choi J, Park BO, Heo WD, Han J, Lee HJ, Lee D, Kang HC, Shong M, Paik SB, Kim DS, Lee JH (2018) BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors. Nat Med 24:1662–1668
3. Ostendorf AP, Gutmann DH, Weisenberg JL (2013) Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 54:1810–1814
4. Bernardo P, Cinalli G, Santoro C (2020) Epilepsy in NF1: a systematic review of the literature. Childs Nerv Syst 36:2333–2350
5. Listernick R, Darling C, Greenwald M, Strauss L, Charrow J (1995) Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 127:718–722
6. Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH (2017) A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology 88:1584–1589
7. Mahdi J, Goyal MS, Griffith J, Morris SM, Gutmann DH (2020) Nonoptic pathway tumors in children with neurofibromatosis type 1. Neurology 95:e1052–e1059
8. Soffietti R, Baumert BG, Bello L, Von Deimling A, Duffau H, Frény M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W (2010) Guidelines on management of low-grade gliomas: report of an EFNS–EANO® Task Force. Eur J Neurol 17:1124–1133
9. Tartaglia M, Gelb BD (2005) Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 6:45–68
10. Patil VV, Guzman M, Carter AN, Rathore G, Yoshour D, Curry D, Wilfong A, Agadi S, Swann JW, Adesina AM, Bhattacharjee MB, Anderson AE (2016) Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia. Neuropathology 36:146–156
11. Nguyen LH, Leiser SC, Dong D, Brunner D, Roberds SL, Wong M, Bordey A (2022) Inhibition of MEK-ERK signalling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy Res 181:106890
12. Kopanitsa MV, Gou G, Afinowi NO, Bayés À, Grant SGN, Komiyama NH (2018) Chronic treatment with a MEK inhibitor reverses enhanced excitatory field potentials in Syngap1(+/-) mice. Pharmacol Rep 70:777–783
13. Carvill GL, Heavin SB, Yendle SC, McMahon JM, O’Roak BJ, Cook J, Khan A, Dorschner MO, Weaver M, Calvert S, Malone S, Wallace G, Stanley T, Bye AME, Bleasel A, Howell KB, Kivity S, Mackay MD, Rodriguez-Casero V, Webster R, Korczyn A, Afawi Z, Zelnick N, Lerman-Sagie T, Lev D, Møller RS, Gill D, Andrade DM, Freeman JL, Sadleir LG, Shendure J, Berkovic SF, Scheffer IE, Melford HC (2013) Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 45:825–830
14. Sharland M, Burch M, McKenna WM, Paton MA (1992) A clinical study of Noonan syndrome. Arch Dis Child 67:178–183
15. Salman MM, Sheilabi MA, Bhattacharyya D, Kitchen P, Conner AC, Bill RM, Woodroofe MN, Conner MT, Princivalle AP (2017) Transcriptome analysis suggests a role for the differential expression of cerebral aquaporins and the MAPK signalling pathway in human temporal lobe epilepsy. Eur J Neurosci 46:2121–2132
16. Houser CR, Huang CS, Peng Z (2008) Dynamic seizure-related changes in extracellular signal-regulated kinase activation in a mouse model of temporal lobe epilepsy. Neuroscience 156:222–237
17. Glazova MV, Nikitina LS, Hudik KA, Kirillova OD, Dorofeeva NA, Korotkov AA, Chernigovskaya EV (2015) Inhibition of ERK1/2 signaling prevents epileptiform behavior in rats prone to audiogenic seizures. J Neurochem 132:218–229
18. Naumova AA, Oleynik EA, Chernigovskaya EV, Glazova MV (2020) Glutamatergic Fate of Neural Progenitor Cells of Rats with Inherited Audiogenic Epilepsy. Brain Sci. 10(5):311
19. Nateri AS, Raivich G, Gebhardt C, Da Costa C, Naumann H, Vreugdenhil M, Makwana M, Brandner S, Adams RH, Jefferys JG, Kann O, Behrens A (2007) ERK activation causes epilepsy by stimulating NMDA receptor activity. EMBO J 26:4891–4901

20. Holter MC, Hewitt LT, Nishimura KJ, Knowles SJ, Bjorklund GR, Shah S, Fry NR, Rees KP, Gupta TA, Daniels CW, Li G, Marsh S, Treiman DM, Olive MF, Anderson TR, Sanabria F, Snider WD, Newborn JM (2021) Hyperactive MEK1 signaling in cortical GABAergic neurons promotes embryonic parvalbumin neuron loss and defects in behavioral inhibition. Cereb Cortex 31:3064–3081

21. Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Campagne O, Banerjee A, Gururangan S, Kilburn LB, Goldman S, Qaddoumi I, Baxter P, Vezina G, Bregman C, Patay Z, Jones JY, Stewart CF, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011–1022

22. Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamraz B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2021) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol 23:1777–1788

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.